Field visit finds dead birds, eggs surrounded by faeces and fly infestations at egg farm whose operators claim to supply Marriott properties
JAKARTA, INDONESIA - Media OutReach Newswire - 1 April 2026 - Marriott International (Marriott) has yet to publicly confirm whether it has met its commitment to source 100% cage-free eggs across all global operations by the end of 2025. A field visit conducted in November 2025 to an egg farm whose operators stated they supply Marriott properties has documented conditions that raise serious animal welfare and hygiene concerns.
Clockwise from top left: a hen with a visible eye injury; a dead bird observed discarded outside the cage structure; flies on a surface near chicken feed troughs. Photos: Resha Juhari / INCAF / We Animals.
In 2018, Marriott committed to sourcing "100% of eggs from cage-free sources throughout the company's global operations for all owned, managed and franchised properties by the end of 2025."
As the deadline approached, the company issued no updates on its cage-free transition despite repeated requests. With no response forthcoming, the Indonesia Network for Compassionate Animal Farming (INCAF) and partner organisations began conducting field visits to egg farms across Asia.
Clockwise from top left: egg trays stored at floor level surrounded by excrement; accumulated waste and debris beneath the cages; the interior of the battery cage facility showing waste buildup and cobwebs across cage structures. Photos: Resha Juhari / INCAF / We Animals.
At a farm whose operators claim to supply to Marriot properties, the following conditions were documented:
- Eggs stored directly on the floor, surrounded by dirt, feathers and excrement
- Swarms of flies around birds and their food
- Accumulated faeces on and underneath cages
- Dead birds discarded around the facility
- Birds with severe eye injuries or blindness
- Birds crammed into dirty wire cages
- Poor access to water
"Marriott claims to 'Serve Our World' as a core value. What we documented at this farm raises serious questions about how that value is being upheld in practice," said Frank Kembuan, Director of INCAF.
The visit is part of a broader Asia-wide movement, with organisations across multiple countries working together to promote transparency and accountability in fulfilling cage-free egg commitments, including China, India, Indonesia, Malaysia, the Philippines and Vietnam.
Marriott has not confirmed whether this farm is part of its current supply chain. The findings in this release are based on statements made by farm operators and field observations conducted by the campaign team. Marriott was approached to verify, respond, and engage constructively prior to publication.
More information from the field visit is available at: www.helpmarriottfindasia.com/field-visit
Hashtag: #HelpMarriottFindAsia #AnimalWelfare #CorporateAccountability #EthicalSourcing #FoodSafety
The issuer is solely responsible for the content of this announcement.
About INCAF
The Indonesia Network for Compassionate Animal Farming works to advance corporate accountability for animal welfare in Indonesia, driving transparency and progress toward cage-free supply chains. Visit https://incaf.org
** This press release is distributed by Media OutReach Newswire through automated distribution system, for which the client assumes full responsibility. **
Advancing Core Product ICVAX® for HIV & Immunotherapy Pipeline for Cancers
HONG KONG SAR – Media OutReach Newswire – 13 November 2026 – Yicura BioMed ("Yicura"), a clinical-stage immunotherapy company based in the Hong Kong Science Park developing medicines for infectious diseases, cancers, and inflammatory diseases, is pleased to announce today the first closing of its Series B financing led by Gobi Partners, with participation from a number of strategic investors from Wuxi and institutional investors from Hong Kong. Their participation reflects shared confidence in Yicura's clinical development path. Proceeds will be deployed to advance the core product ICVAX® for HIV and to accelerate the development of the immunotherapy pipeline for cancers across the vaccine and antibody programmes.
ICVAX® has completed a randomised, placebo-controlled NMPA-approved Phase I clinical trial in people living with HIV on antiretroviral therapy, with favourable safety and immunogenicity performance. The program is advancing to Phase II clinical trial for efficacy evaluation for a more durable immune control of HIV and the target path to functional cure.
"This funding round marks an important step in Yicura's growth as we move ICVAX® from early clinical validation towards efficacy studies," Dr. Xia JIN, Co-Founder and CEO of Yicura, said. "We are encouraged by the Phase I data of ICVAX® and the potential of our PD-1-enhanced DNA vaccine and anti-∆42PD1 antibody platforms to address serious unmet needs in infectious diseases, cancers and inflammation. We are grateful for Gobi Partners' partnership and the investors' confidence in our science, our team and our mission to develop immunotherapies that can meaningfully change the standard of care for patients."
"Yicura is building a distinctive suite of immunotherapies from Hong Kong, with a clear clinical lead in ICVAX® and platform technologies that can extend well beyond a single indication to precision therapies for cancers." Mr. Fred LI, Managing Director and Head of University Ventures of Gobi Partners, shared, "We are pleased to lead this Series B financing and to support Dr. JIN and the Yicura team as they advance the promising HIV therapeutic vaccine and continue to translate their brilliant technologies into medicines for patients in need."
Hashtag: #醫克生物 #Yicura
http://www.yicura.hk
https://www.linkedin.com/company/yicura
The issuer is solely responsible for the content of this announcement.
About Yicura BioMed (formerly known as Immuno Cure)
Yicura BioMed ("Yicura") is a clinical-stage biotechnology group based in the Hong Kong Science Park, focusing on research and development of immunotherapies for cancers, inflammations, and infectious diseases based on its patented PD-1-enhanced DNA vaccine and anti-Δ42PD1 antibody platforms.
To learn more about Yicura, please visit: http://www.yicura.hk
About Gobi Partners
Founded in 2002, Gobi Partners is a leading pan-Asian investment firm specialising in bespoke capital solutions for family offices, sovereign wealth funds, financial institutions and corporate investors. Headquartered in Hong Kong and Kuala Lumpur, Gobi manages US$2 billion across 30+ investment vehicles, investing in early to growth-stage companies with the potential for generational and global impact.
The firm's team of over 90 investment professionals operates from 18 locations, curating a diversified portfolio of more than 400 companies, with 76 exits achieved to date. Gobi is recognised for its long-term, values-aligned approach, building ecosystems at the intersection of technology, sustainability, and inclusion. From pioneering TaqwaTech for two billion Muslims, to advancing the circular economy, to promoting gender-diverse leadership, Gobi backs the trends that are reshaping societies.
Gobi's edge lies in identifying structural and demographic shifts, forging partnerships with universities and institutions of higher education; bridging world-class research with private capital and bringing deep technology breakthroughs to commercialisation.
Official Website: https://gobi.vc
Official Linkedin: https://www.linkedin.com/company/gobipartners/
** This press release is distributed by Media OutReach Newswire through automated distribution system, for which the client assumes full responsibility. **
